Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review

Blangé, Dionne; Stroes, Charlotte I.; Derks, Sarah; Bijlsma, Maarten F.; Laarhoven, H.W.M. van

doi:10.1016/j.ctrv.2022.102418

Cited by 19 publications

(18 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, prognostic evaluation is referred to the tumor node metastasis (TNM) classification standard. But the drug response and individual variation would also affect the outcome of gastric cancer, due to the tumor mutation burden (TMB) (Chen et al, 2022;Lee et al, 2022) and drug-resistant status (Wang et al, 2022a;Blange et al, 2022;Zhong et al, 2022). Therefore, it is urgently needed to identify novel powerful prognostic markers and to predict the drug sensitivity status for gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

Metal-dependent programmed cell death-related lncRNA prognostic signatures and natural drug sensitivity prediction for gastric cancer

et al. 2022

View full text Add to dashboard Cite

Background: Gastric cancer is one of the most important malignancies with poor prognosis. Ferroptosis and cuproptosis are newly discovered metal-dependent types of programmed cell death, which may directly affect the outcome of gastric cancer. Long noncoding RNAs (lncRNAs) can affect the prognosis of cancer with stable structures, which could be potential prognostic prediction factors for gastric cancer.Methods: Differentially expressed metal-dependent programmed cell death (PCD)-related lncRNAs were identified with DESeq2 and Pearson’s correlation analysis. Through GO and KEGG analyses and GSEA , we identified the potential effects of metal-dependent PCD-related lncRNAs on prognosis. Using Cox regression analysis with the LASSO method, we constructed a 12-lncRNA prognostic signature model. Also, we evaluated the prognostic efficiency with Kaplan–Meier (K-M) survival curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA) methods. The sensitivities for antitumor drugs were then predicted with the pRRophetic method. Also, we discuss Chinese patent medicines and plant extracts that could induce metal-dependent programmed cell death.Results: We constructed a metal-dependent PCD-related lncRNA-gene co-expression network. Also, a metal-dependent PCD-related gastric cancer prognostic signature model including 12 lncRNAs was constructed. The K-M survival curve revealed a poor prognosis in the high-risk group. ROC curve analysis shows that the AUC of our model is 0.766, which is better than that of other published models. Moreover, the half-maximum inhibitory concentration (IC50) for dasatinib, lapatinib, sunitinib, cytarabine, saracatinib, and vinorelbine was much lower among the high-risk group.Conclusion: Our 12 metal-dependent PCD-related lncRNA prognostic signature model may improve the OS prediction for gastric cancer. The antitumor drug sensitivity analysis results may also be helpful for individualized chemotherapy regimen design.

show abstract

Section: Introductionmentioning

confidence: 99%

Metal-dependent programmed cell death-related lncRNA prognostic signatures and natural drug sensitivity prediction for gastric cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In this context, dual targeting of HER3 or MET seems to be one of the most promising mechanisms, which could overcome the resistance of cancer cells against anti‐HER1 and anti‐HER2 therapy. 11 , 12 , 53 , 54 , 55 …”

Section: Discussionmentioning

confidence: 99%

“…However, it is not easy to search for effective molecules for co‐targeting from huge combinations, as in the example of co‐targeting of IGF1R with aromatase inhibitor, estrogen receptor antagonist, 50,51 or HER2 inhibitor, 52 which has resulted in the poor clinical response. In this context, dual targeting of HER3 or MET seems to be one of the most promising mechanisms, which could overcome the resistance of cancer cells against anti‐HER1 and anti‐HER2 therapy 11,12,53–55 …”

Section: Discussionmentioning

confidence: 99%

Dual‐targeting therapy against HER3/MET in human colorectal cancers

et al. 2023

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) is the most common malignancy in the world, and novel molecular targeted therapies for CRC have been vigorously pursued. We searched for novel combination therapies based on the expression patterns of membrane proteins in CRC cell lines. Results A positive correlation was observed between the expression of human pidermal growth factor receptor (HER) 3 and mesenchymal‐to‐epithelial transition factor (MET) on the cell surface of CRC cell lines. The brief stimulation of HER3/MET‐high SW1116 CRC cells with both neuregulin‐1 (NRG1) and hepatocyte growth factor enhanced ERK phosphorylation and cell proliferation more than each stimulation alone. In addition, a prolonged NRG1 stimulation resulted in the tyrosine phosphorylation of MET. In this context, the Forkhead Box protein M1 (FOXM1)‐regulated tyrosine phosphorylation of MET by NRG1 was demonstrated, suggesting the existence of a signaling pathway mediated by FOXM1 upon the NRG1 stimulation. Since the co‐expression of HER3 and MET was also demonstrated in in vivo CRC tissues by immunohistochemistry, we investigated whether the co‐inhibition of HER3 and MET could be an effective therapy for CRC. We established HER3‐and/or MET‐KO SW1116 cell lines, and HER3/MET‐double KO resulted in the inhibition of in vitro cell proliferation and in vivo tumor growth in nude mice by SW1116 cells. Furthermore, the combination of patritumab, an anti‐HER3 fully human mAb, and PHA665752, a MET inhibitor, markedly inhibited in vitro cell proliferation, 3D‐colony formation, and in vivo tumor growth in nude mice by SW1116 cells Conclusion The dual targeting of HER3/MET has potential as CRC therapy.

show abstract

“…With advances in high-throughput sequencing techniques, several genomic classification systems that reflect the complicated genomic mechanisms underlying GC have been proposed ( 37 , 38 ). The complicated alternation of the signaling pathways induced by HER2 overexpression underlies the treatment efficacy of anti-HER2 therapy ( 39 , 40 ). Thus, further radiogenomics analysis that links radiomics features with the genomic profile is warranted in future research.…”

Section: Discussionmentioning

confidence: 99%

A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer

Ma¹,

Cui²,

Wang³

et al. 2022

Transl Cancer Res

View full text Add to dashboard Cite

Background: Accurate evaluation of human epidermal growth factor receptor 2 (HER2) status is very important for appropriate management of advanced gastric cancer (AGC) patients. In this study, we aimed to develop and validate a computed tomography (CT)-based radiomics signature for preoperative prediction of HER2 overexpression and treatment efficacy of trastuzumab in AGC. Methods:We retrospectively enrolled 536 consecutive AGC patients (median age, 59 years; interquartile range, 52-65 years; 377 male, 159 female) and separated them into a training set (n=357) and a testing set (n=179). Radiomic features were extracted from 3 different phase images of contrast-enhanced CT scans, and a radiomics signature was built based on highly reproducible features using the least absolute shrinkage and selection operator (LASSO) method. The predictive performance of the radiomics signature was assessed in the training and testing sets. Univariable and multivariable logistical regression analyses were used to identify independent risk factors of HER2 overexpression. Univariable and multivariable Cox regression analyses were used to identify the risk factors of overall survival (OS) and progression-free survival (PFS).The predictive value of the radiomics signature for treatment efficacy of trastuzumab was also evaluated. Results:The radiomics signature comprised eight robust features that demonstrated good discrimination ability for HER2 overexpression in the training set [area under the curve (AUC) =0.85] and the testing set (AUC =0.81). Multivariable Cox regression analysis revealed that the radiomics signature was an independent risk factor for OS [hazard ratio (HR) =2.01, P=0.001] and PFS (HR =1.32, P=0.01). The radiomics score of patients who achieved disease control was significantly lower than that of patients with progressive disease (P=0.023). Conclusions:The proposed radiomics signature showed favorable accuracy for prediction of HER2 overexpression and prognosis in AGC. It has promising potential as a noninvasive approach for selecting patients for target therapy.

show abstract

Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review

Cited by 19 publications

References 122 publications

Metal-dependent programmed cell death-related lncRNA prognostic signatures and natural drug sensitivity prediction for gastric cancer

Metal-dependent programmed cell death-related lncRNA prognostic signatures and natural drug sensitivity prediction for gastric cancer

Dual‐targeting therapy against HER3/MET in human colorectal cancers

A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer

Contact Info

Product

Resources

About